Key Takeaways
A healthcare software company Phreesia Inc. is facing multiple class-action lawsuits after its stock plunged 27% on news of a lowered revenue outlook for fiscal year 2027.
"Defendants failed to disclose that Phreesia’s pharmaceutical marketing commitments within its Network Solutions segment were weakening," according to a complaint filed by Robbins LLP, one of several firms initiating legal action.
On March 30, 2026, Phreesia cut its fiscal 2027 revenue guidance to a range of $510 million to $520 million. The company had previously forecast a range of $545 million to $559 million. Management attributed the change to "shorter visibility into spending commitments" from certain pharmaceutical manufacturers.
The lawsuits allege the company misled investors about its growth sustainability, leading to artificially inflated stock prices during the class period from May 8, 2025, to March 30, 2026. The stock fell from $11.41 to $8.38 per share on the news.
The class action complaints, filed by firms including Pomerantz LLP, Robbins LLP, and The Portnoy Law Firm, center on Phreesia's Network Solutions business. The lawsuits claim the company was aware of, but did not disclose, weakening client demand and reduced future spending commitments.
Plaintiffs allege that these omissions created a false impression of sustainable growth. On an earnings call, the company further disclosed that some clients were committing fewer marketing dollars because of "brand-specific dynamics including the impact of regulatory policies," according to the Robbins LLP complaint.
The sharp stock decline erased significant market value, prompting the legal actions on behalf of shareholders who purchased stock during the nearly 11-month class period.
The lawsuits seek to recover damages for investors. The deadline for shareholders to file a lead plaintiff motion with the court is July 13, 2026.
This article is for informational purposes only and does not constitute investment advice.
